As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022.

Researchers at the Keck School of Medicine of USC have identified a biological feedback loop that helps explain why certain colorectal cancers—known as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR) tumors—respond better to immunotherapy. Using mouse models and patient tumor data, the team found that two genes, DR5 and Lig3, drive a cycle of tumor cell death and immune activation by promoting the release of extrachromosomal circular DNA, which amplifies the immune response. Tumors with higher DR5 and Lig3 activity were more likely to respond to immune checkpoint inhibitors, suggesting a potential pathway to improve treatment and better predict which patients will benefit from immunotherapy.